Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Avastin (Bevacizumab) Market Value Growth And Long-Term Outlook
The avastin (bevacizumab) market has experienced significant growth over recent years. It is projected to increase from $7.82 million in 2025 to $8.43 million in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical expansion is attributable to factors such as the clinical validation of VEGF inhibition, the rising global burden of cancer, broad label expansion approvals, substantial oncologist familiarity, and its early adoption in colorectal cancer.
The market for avastin (bevacizumab) is projected to experience robust expansion over the coming years. This market is forecast to reach $11.27 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this growth during the projected period include the rise of bevacizumab biosimilars, a growing pool of oncology patients, greater adoption in developing markets, the need for economical biologics, and improvements in combination therapy regimens. Key trends anticipated for the forecast timeframe encompass the sustained application of anti-angiogenic cancer treatments, the broader utilization of avastin for various cancer types, an increase in combination therapies involving chemotherapy, growing acceptance in ophthalmic uses, and heightened attention on biosimilar rivalry.
Get A Free Sample Report With In-Depth Market Insights:
Avastin (Bevacizumab) Market Demand Drivers Opening New Revenue Streams
The escalating prevalence of cancer is anticipated to fuel the expansion of the avastin (bevacizumab) market moving forward. Cancer is a general term describing a group of illnesses marked by the unregulated proliferation and dissemination of abnormal cells throughout the body. The rise in cancer cases is attributed to factors like an aging demographic, changes in lifestyle, and improved diagnostic methods. Avastin treats cancer by impeding VEGF, thereby obstructing the development of blood vessels that supply oxygen and nutrients to tumors, effectively depriving them. For instance, in August 2024, according to the Macmillan Cancer Support, a UK-based organization, it was reported that in 2024, over 3 million individuals in the UK are living with cancer, a figure projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the growing incidence of cancer is a key driver for the avastin (bevacizumab) market. The increasing healthcare expenditure is set to propel the growth of the avastin (bevacizumab) market in the coming years. Healthcare expenditure refers to the total funds allocated to health goods and services, including personal health care, preventative measures, and public health activities, all aimed at enhancing health outcomes within a specified timeframe. The surge in healthcare spending is driven by an aging population, chronic conditions, advanced medical technologies, high drug costs, inefficient payment systems, and heightened demand for services. This expenditure benefits Avastin (bevacizumab) by enhancing access to the medication through insurance coverage, thus supporting its market expansion and broader patient utilization. For example, in May 2024, a report from the Office for National Statistics, a UK-based government agency, indicated that total healthcare spending increased by 5.6% in nominal terms from 2022 to 2023, significantly higher than the 0.9% growth rate recorded in 2022. Therefore, the rising healthcare expenditure is a primary factor driving the avastin (bevacizumab) market.
Avastin (Bevacizumab) Market Segment Landscape And Growth Outlook
The avastin (bevacizumab) market covered in this report is segmented –
1) By Dosage: 100 Mg, 400 Mg
2) By Application: Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Other Applications
3) By Distribution channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End User: Hospitals, Cancer Supportive Centers, Home Healthcare, Academic And Research Institutes, Other End Users
Avastin (Bevacizumab) Market Trends Powering Strategic Industry Growth
Leading companies in the Avastin (bevacizumab) market are increasingly focusing on the expansion of biosimilars, including prominent bevacizumab biosimilars, to achieve a competitive advantage. This biosimilar proliferation signifies a rapid surge in the availability and quantity of biosimilar drugs in the marketplace. For instance, in December 2023, Bio Thera Solutions, a biopharmaceutical company based in China, obtained FDA approval for Avzivi (bevacizumab tnjn), an Avastin biosimilar, which demonstrated equivalent efficacy, safety, and immunogenicity to its reference product. Furthermore, in July 2024, the European Medicines Agency (EMA) also granted approval to BAT1706 / Avzivi for various oncology indications. These advancements are promoting increased affordability and accessibility for patients. Nevertheless, they also escalate pricing pressure on the originator product, pose a challenge to market share, and require significant manufacturing capacity from new market entrants.
Avastin (Bevacizumab) Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the avastin (bevacizumab) market are Roche Holding AG
View The Full Avastin (Bevacizumab) Market Report:
Avastin (Bevacizumab) Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
